Daily Roundup
Thursday, 19th November 2026 · updated 08:00
The a2 Milk Company is signaling cautious optimism as it charts a recovery path in one of its most critical markets. The company's China infant milk formula business has bounced back to roughly half of what it was pulling in before supply chain disruptions hit, marking meaningful progress on a key turnaround effort.
Looking ahead to FY27, a2 Milk expects its overall revenue and EBITDA to grow, buoyed by product innovation, expansion into new markets, and improving profitability from its a2 Pããkeno brand. However, the company isn't expecting a dramatic rebound in infant formula sales just yet—IMF revenues are projected to stay roughly in line with FY26 levels, though the company does anticipate a meaningful recovery kicking in during the second half of the year.
The company is guiding for mid-single-digit revenue growth in FY27 and targeting an EBITDA margin of approximately 15%, with depreciation and amortization running around $20 million. It's worth noting that earnings will likely be heavily weighted toward the latter half of the year, reflecting the expected timing of the China IMF recovery and other growth initiatives.